COMPASS Pathways plc (CMPS): Long-Term Debt
$31.63M
As of 2025-12-31
$50.73M
As of 2026-06-30
| Period ended | Long-Term Debt | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $31.63M | +4.9% | 2026-03-24, Balance as of period end |
| 2024-12-31 | $30.16M | +4.9% | 2026-03-24, Balance as of period end |
| 2023-12-31 | $28.76M | n/a | 2024-02-29, Balance as of period end |
| 2022-12-31 | $0 | n/a | 2024-02-29, Balance as of period end |
Long-Term Debt at similar companies
| Company | Year ended | Long-Term Debt | Change YoY |
|---|---|---|---|
| COMPASS Pathways plc (CMPS) | 2025-12-31 | $31.63M | +4.9% |
| Puma Biotechnology, Inc. (PBYI) | 2025-12-31 | $22.68M | -66.7% |
| Abeona Therapeutics Inc. (ABEO) | 2025-12-31 | $20.04M | +5.7% |
| UroGen Pharma Ltd. (URGN) | 2025-12-31 | $125.00M | n/a |
| Pliant Therapeutics, Inc. (PLRX) | 2025-12-31 | $0 | -100.0% |
| Evolus, Inc. (EOLS) | 2025-12-31 | $146.10M | +20.2% |
| Fortress Biotech, Inc. (FBIO) | 2025-12-31 | $52.42M | -9.6% |
| Lifecore Biomedical, Inc. (LFCR) | 2025-05-25 | $130.44M | +4.6% |
| Alto Neuroscience, Inc. (ANRO) | 2024-12-31 | $10.25M | n/a |
Compare CMPS, PBYI, ABEO, URGN side by side · Screen every company in Pharmaceutical Preparations ↗